We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Diagnostic Test Developed for Mixed Malaria Infections

By LabMedica International staff writers
Posted on 29 Dec 2011
A rapid diagnostic test (RDT) has been developed and evaluated as a mixed-species infections malaria antigen (FVM Ag) detection kit. More...


The kit, which uses monoclonal antibodies, can identify both single-species Plasmodium falciparum or P. vivax infections, and mixed infections with these two species.

Scientists at the Chungbuk National University (Republic of Korea) prepared colloidal gold–conjugated monoclonal antibodies applied to cellulose paper strips. They produced three monoclonal antibodies that recognize the lactate dehydrogenase of P. falciparum, P. vivax, or both to develop the first mixed-species infections malaria antigen-detection kit. They evaluated the sensitivity of the test and compared it with comparable commercial RDTs.

The sensitivity and specificity of the kit was assessed with 722 clinical specimens. The detection limit of 150 parasites/μL for the FVM Ag RDT for P. falciparum-positive blood samples was higher than that of the two commercial RDTs, which was less than 60 parasites/μL. The detection limit of the RDT for P. vivax-positive specimens was 250 parasites/μL, which was the same as that of the NanoSign Malaria Pf/Pan Ag kit (Bioland Ltd; Ochang, Korea) and lower than that of the 500 parasites/μL for the BioLine Malaria Pf/Pan Ag kit (Standard Diagnostics Inc.; Suwon, Korea). The results of the study showed that the FVM Ag RDT has sensitivities for P. falciparum, P. vivax, and mixed-species infection were 96.5%, 95.3%, and 85.7%, respectively. In addition, its specificity was as high as 99.4%.

P. falciparum and P. vivax malaria are endemic to many parts of the world and humans can be coinfected with both species. Because each Plasmodium species has different biological and clinical characteristics, accurate differentiation of the infecting species is essential for effective treatment. Although microscopy is still the gold standard for malaria diagnosis, it requires experienced technicians and a microscope, which are not always available in remote areas. The authors of the study concluded that the FVM Ag kit is the first RDT with the capability to differentiate malaria species. They anticipate that their RDT will be a useful diagnostic tool that will help improve the diagnosis and treatment of malaria, particularly in remote areas of the world. The study was published the December 2011 issue the American Journal of Tropical Medicine and Hygiene.

Related Links:
Chungbuk National University
Bioland Ltd.
Standard Diagnostics Inc.



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.